Heartflow CFO Vikram Verghese sells $1.23m in company stock

Vikram Verghese, CFO of Heartflow Inc., divested $1.23 million worth of the company's stock in two transactions on September 17 and 18, 2026. The sales were made under a pre-arranged Rule 10b5-1 trading plan, adopted on June 4, 2026. The stock was trading near its 52-week high of $52.22 at the time of sale, currently priced at $49.17.

According to InvestingPro Tips, Heartflow delivered strong returns over the past three months and significant gains over the last six months, with a 99% increase over six months. However, the stock is currently considered overvalued according to InvestingPro analysis. Verghese sold 7,579 shares on September 17, at prices ranging from $50.00 to $50.29 per share, followed by an additional 16,766 shares on September 18, sold at prices between $50.00 and $52.11 per share.

After these transactions, he directly owns 155,183 shares of Heartflow common stock. Heartflow reported a narrower-than-expected loss for Q2 2026, with adjusted earnings of -$0.07 per share, beating expectations of -$0.19. Revenue for the quarter rose by 48% to $64.1 million, driven by increased demand for its coronary artery disease diagnostics.

This revenue surpassed both Stifel's projection ($56.7 million) and consensus estimates ($56.6 million). As a result, Stifel raised its price target for HeartFlow shares to $45, maintaining a Buy rating. Canaccord also raised its price target to $56, while maintaining a Buy rating, based on an expanded plaque analysis survey. These developments indicate growing interest and a positive outlook from analysts regarding HeartFlow's performance and potential.